Rani Therapeutics Q3 net loss decreases, extends cash runway into 2028
I'm PortAI, I can summarize articles.
Rani Therapeutics reported a Q3 net loss of $7.9 million, down from $12.7 million in Q3 2024. The company completed a $60.3 million oversubscribed private placement, extending its cash runway into 2028. Rani plans to initiate a Phase 1 trial for RT-114 by the end of 2025. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $10.50, representing a 76.2% upside from its recent closing price of $2.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments